• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急诊科和医院中慢性阻塞性肺疾病的成本:对来自218家美国医院的行政数据的分析

Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US Hospitals.

作者信息

Stanford Richard H, Shen Yingjia, McLaughlin Trent

机构信息

GlaxoSmithKline, Research Triangle Park, North Carolina, USA.

出版信息

Treat Respir Med. 2006;5(5):343-9. doi: 10.2165/00151829-200605050-00005.

DOI:10.2165/00151829-200605050-00005
PMID:16928147
Abstract

STUDY OBJECTIVES

Treatment of chronic obstructive pulmonary disease (COPD) in the emergency department (ED) or hospital accounts for a significant portion of COPD costs. This study estimates the cost of a COPD ED or hospitalization visit in the US.

DESIGN

This observational study utilized administrative data from 218 acute care hospitals. ED/hospital discharges for COPD (International Classification of Diseases - Ninth Revision - Clinical Modification codes 491.xx. 492.xx, 496.xx) during 2001 were identified. Costs were determined for three groups: (i) ED only; (ii) standard admission; and (iii) severe admissions (intensive care unit [ICU] or intubation). Severe admissions were stratified into: (i) ICU/no intubation; (ii) intubation/no ICU; and (iii) ICU + intubation. Mean total costs and length of stay (LOS) were calculated for each group.

RESULTS

A total of 59 735 ED/hospital encounters were identified: 20 431 ED only, 33 210 standard admissions, and 6094 severe admissions (4456 ICU/no intubation, 496 intubation/no ICU, and 1142 ICU/intubation). ED visits had a mean cost of $US571 +/- 507 (year 2001 value). Inpatient costs ranged from $US5997 (+/- 5752) for a standard admission to $US36 743 (+/- 62 886) for ICU plus intubation admissions, while LOS ranged from 5.1 days (+/- 4.5) to 14.8 days (+/- 16.7), respectively. In addition, only 10% of encounters required an intubation/ICU admission, but these accounted for 34% of the cost.

CONCLUSION

Cost of a COPD hospitalization is substantial in the US, with one-third of those costs being associated with severe admissions, which make up only 10% of all COPD admissions. Treatments aimed at reducing hospitalizations and length of stay could result in substantial cost savings.

摘要

研究目标

急诊科(ED)或医院对慢性阻塞性肺疾病(COPD)的治疗占COPD治疗费用的很大一部分。本研究估算了美国COPD患者急诊或住院治疗的费用。

设计

这项观察性研究使用了来自218家急性护理医院的管理数据。确定了2001年期间因COPD(国际疾病分类第九版临床修订本编码491.xx、492.xx、496.xx)而进行的急诊/出院情况。确定了三组的费用:(i)仅急诊;(ii)标准住院;(iii)重症住院(重症监护病房[ICU]或插管)。重症住院又分为:(i)ICU/未插管;(ii)插管/未进ICU;(iii)ICU + 插管。计算了每组的平均总费用和住院时间(LOS)。

结果

共确定了59735次急诊/住院情况:仅急诊20431次,标准住院33210次,重症住院6094次(4456次ICU/未插管,496次插管/未进ICU,1142次ICU/插管)。急诊就诊的平均费用为571美元±507美元(2001年价值)。住院费用从标准住院的5997美元(±5752美元)到ICU加插管住院的36743美元(±62886美元)不等,而住院时间分别从5.1天(±4.5天)到14.8天(±16.7天)不等。此外,只有10%的情况需要插管/进ICU住院,但这些病例占费用的34%。

结论

在美国,COPD住院费用很高,其中三分之一的费用与重症住院有关,而重症住院仅占所有COPD住院病例的10%。旨在减少住院次数和住院时间的治疗方法可能会大幅节省费用。

相似文献

1
Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US Hospitals.急诊科和医院中慢性阻塞性肺疾病的成本:对来自218家美国医院的行政数据的分析
Treat Respir Med. 2006;5(5):343-9. doi: 10.2165/00151829-200605050-00005.
2
Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.与异丙托溴铵相比,使用丙酸氟替卡松500微克/沙美特罗50微克进行初始维持治疗的老年人慢性阻塞性肺疾病住院/急诊就诊风险及治疗费用。
Am J Geriatr Pharmacother. 2008 Aug;6(3):138-46. doi: 10.1016/j.amjopharm.2008.08.005.
3
Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS).慢性阻塞性肺疾病的就诊情况及其预测因素:一项使用美国国家急诊科样本(NEDS)的研究。
Respir Res. 2016 Jan 6;17:1. doi: 10.1186/s12931-015-0319-y.
4
Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.长期护理机构中医疗保险受益人的慢性阻塞性肺疾病负担
Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.
5
Economic burden and secondary complications of influenza-related hospitalization among adults in the US: a retrospective cohort study.美国成年人因流感相关住院的经济负担和次要并发症:一项回顾性队列研究。
J Med Econ. 2024 Jan-Dec;27(1):324-336. doi: 10.1080/13696998.2024.2314429. Epub 2024 Feb 22.
6
Direct costs of chronic obstructive pulmonary disease among managed care patients.管理式医疗患者慢性阻塞性肺疾病的直接成本。
Int J Chron Obstruct Pulmon Dis. 2010 Oct 5;5:341-9. doi: 10.2147/COPD.S13771.
7
Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.根据初始药物治疗方案,对德克萨斯州医疗补助慢性阻塞性肺疾病患者历史队列中的住院情况、急诊科就诊情况及费用进行比较。
Clin Ther. 2007 Jun;29(6):1203-13. doi: 10.1016/j.clinthera.2007.06.006.
8
Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population.在管理式医疗的医疗保险人群中,与慢性阻塞性肺疾病治疗相关的医院和急诊科利用率。
Curr Med Res Opin. 2009 Nov;25(11):2729-35. doi: 10.1185/03007990903267157.
9
National growth in intensive care unit admissions from emergency departments in the United States from 2002 to 2009.美国 2002 年至 2009 年急诊科重症监护病房入院人数的国家增长情况。
Acad Emerg Med. 2013 May;20(5):479-86. doi: 10.1111/acem.12134.
10
Cost-effectiveness of 'Program We Care' for patients with chronic obstructive pulmonary disease: A case-control study.“关爱计划”对慢性阻塞性肺疾病患者的成本效益:一项病例对照研究。
Int Emerg Nurs. 2016 Jul;27:37-41. doi: 10.1016/j.ienj.2015.11.001. Epub 2015 Dec 2.

引用本文的文献

1
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.慢性阻塞性肺疾病(COPD)经济负担:系统文献回顾。
Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:439-460. doi: 10.2147/COPD.S234942. eCollection 2020.
2
Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.每日两次吸入茚达特罗/格隆溴铵粉剂治疗美国中重度慢性阻塞性肺疾病的成本效益
Int J Chron Obstruct Pulmon Dis. 2018 Nov 28;13:3867-3877. doi: 10.2147/COPD.S177097. eCollection 2018.
3
Clinical factors and comorbidities affecting the cost of hospital-treated COPD.
影响住院治疗慢性阻塞性肺疾病费用的临床因素及合并症。
Int J Chron Obstruct Pulmon Dis. 2016 Dec 2;11:3023-3030. doi: 10.2147/COPD.S120637. eCollection 2016.
4
Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study.慢性阻塞性肺疾病住院患者的成本分析:一项州级横断面研究。
Tanaffos. 2016;15(2):75-82.
5
Direct costs of chronic obstructive pulmonary disease among managed care patients.管理式医疗患者慢性阻塞性肺疾病的直接成本。
Int J Chron Obstruct Pulmon Dis. 2010 Oct 5;5:341-9. doi: 10.2147/COPD.S13771.
6
Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.丙酸氟替卡松-沙美特罗 250/50 微克联合用药与沙美特罗治疗重度 COPD 患者的成本效益比较。
Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:179-87. doi: 10.2147/copd.s10988.
7
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.丙酸氟替卡松/沙美特罗联合治疗在预防 COPD 恶化中的作用。
Int J Chron Obstruct Pulmon Dis. 2010 Jun 3;5:165-78. doi: 10.2147/copd.s4159.